MIMEDX Announces Publication in the Journal of Inflammation Focused on Immunomodulatory Effects of Purion® Processed Human Amniotic Membrane Allografts In Vitro

Core Insights - The study published in the Journal of Inflammation highlights the immunomodulatory effects of MiMedx's DHACM and LHACM products, supporting their role in tissue repair and healing [1][2] - The findings indicate that these allografts can regulate inflammatory responses and enhance pro-reparative functions, making them promising interventions for chronic wounds [2] Group 1: Study Findings - The study evaluated DHACM and LHACM allografts for their ability to influence inflammatory monocyte and macrophage biology, demonstrating a multifactorial immunomodulatory effect [2] - The research suggests that DHACM and LHACM can help restore the normal wound-healing cascade, which is often disrupted in complex wounds characterized by persistent inflammation [2] Group 2: Company Overview - MiMedx is a leader in providing solutions for chronic and hard-to-heal wounds, with a focus on innovation in the wound care, burn, and surgical sectors [3] - The company's vision is to be the leading global provider of healing solutions, emphasizing the importance of high-quality evidence in their product offerings [2][3]